These PDx anitbodies likely have a range of epitopes, affinities, Fc functions, glycosylations, etc.–all of which could affect activity, but differential activity isn’t likely predictable from preclinical work. And in the real-world setting many of the nuanced differences may disappear in the face of disease complexity.
Will Anti-CD47 crash the party?
http://www.forbes.com/sites/brucebooth/2016/06/22/immuno-oncology-the-strategic-supernova-in-cancer-today/#59576c8e1d44
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM